Table 1.
Targeted therapies currently in clinical trial development for MTC.
| Drug | Target | Mechanism of action |
|---|---|---|
| Zactima (ZD6474) | VEGFR, RET, EGFR (HER1) | Tyrosine kinase inhibitor |
| XL184 | VEGFR2, MET, RET | Tyrosine kinase inhibitor |
| Imatinib (STI571) | bcr-abl, PDGFR, C-KIT | Tyrosine kinase inhibitor |
| Sorafinib (BAY-43-9006) | BRAF, CRAF, VEGFR, RET, PDGFR | Tyrosine kinase inhibitor |
| Sunitinib (SU11248) | VEGFR, RET, PDGFR, C-KIT, CSF-1R, flt3 | Tyrosine kinase inhibitor |
| AMG-706 | VEGFR1-3, PDGFR, C-KIT | Tyrosine kinase inhibitor |
| Gefitinib | EGFR (HER1) | Tyrosine kinase inhibitor |
| Axitinib (AG-013736) | VEGFR, PDGFR, C-KIT | Tyrosine kinase inhibitor |
| Pazopanib (GW786034) | VEGFR1-3, PDGFR, C-KIT | Tyrosine kinase inhibitor |
| SAHA | Notch1, TNF-α, IL-1-β, IL-6, IFN-γ | HDAC inhibitor |
| Lithium | GSK-3ß | Unknown, suspected GSK3 inhibition, inositol depletion |